Movement Alert|Revolution Medicines, Inc. Pre-Market Rise 4.1%, EU Approves Rasonque for Metastatic Pancreatic Cancer

Market Focus
Nov 20

On November 20, Revolution Medicines, Inc. rose 4.1% in Pre-Market Trading, with the stock trading at $164.0 and turnover of $53.26 thousand.

The clearest catalyst is the company’s recently disclosed European Commission approval of Rasonque monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, with or without an identified RAS tumor mutation.

The authorization covers European Union member states and the European Economic Area, though not the UK or Switzerland. The approval was supported by a phase 3 trial that met all primary and key secondary endpoints, extending the drug’s commercial reach beyond the US. Supporting sentiment has also remained constructive, with RBC earlier raising its price target to $321 and maintaining an Outperform rating after the company’s latest quarterly update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10